...
首页> 外文期刊>European archives of oto-rhino-laryngology: Official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) >Factors influencing the outcome of idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy.
【24h】

Factors influencing the outcome of idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy.

机译:高压氧治疗影响特发性突然感觉神经性听力减退结果的因素。

获取原文
获取原文并翻译 | 示例
           

摘要

Idiopathic sudden sensorineural hearing loss (ISSNHL) is an otologic emergency with an incidence of about 5-20 per 100,000 of the population per year. There is no universally accepted standard protocol for the treatment of patients with ISSNHL. Hyperbaric oxygen therapy (HBOT), was first reported to improve the outcome following acute inner ear disorders during the late 1960s by both French and German authors. The increase in perilymph oxygenation produced by HBOT provides logical basis for the use of this treatment modality in ISSNHL. We reviewed the records of 97 cases that received HBOT for SSNHL to identify the factors that may affect the treatment outcomes. The effects of age, gender, affected ear, status of the contralateral ear, symptoms associated with hearing loss, presence of a cardiovascular disease, dyslipidemia, history of diabetes mellitus, seasonal factor, smoking, degree of hearing loss, audiogram type, medical treatments provided prior to HBOT, onset time, and number of HBOT sessions were evaluated. The mean hearing gain in all cases after the HBOT was 29.5 dB. The gains were statistically significant in the following cases: early onset of HBOT (p = 0.016), higher number of HBOT sessions (p < 0.01), steroid usage (p = 0.009), low frequency-ascending and total audiogram configuration (p < 0.01) and profound hearing loss (p = 0.011). The success rate was significantly lower in cases with high frequency-descending audiogram configuration (p < 0.001). The most important factor affected the prognosis favorably was found as steroid therapy. This retrospective study and our clinical experience suggest that HBOT has beneficial effects when administered in the early phase of the disease together with steroids. HBOT is a safe practice when used properly by an experienced hyperbaric team. In the treatment of ISSNHL, 20 sessions of HBOT at 2.5 ATA can be tolerated well besides some minor side effects. HBOT should be considered for the cases especially with total or profound hearing loss.
机译:特发性突发性感音神经性听力丧失(ISSNHL)是耳科急症,每年每10万人中约有5-20例发病。没有普遍接受的用于治疗ISSNHL患者的标准方案。法国和德国作者首次报道了高压氧疗法(HBOT)在1960年代后期改善了急性内耳疾病后的疗效。 HBOT产生的外周淋巴氧合增加为在ISSNHL中使用这种治疗方式提供了逻辑依据。我们回顾了97例SSNHL接受HBOT的病例的记录,以确定可能影响治疗结果的因素。年龄,性别,受影响的耳朵,对侧耳朵的状况,与听力下降有关的症状,是否存在心血管疾病,血脂异常,糖尿病史,季节性因素,吸烟,听力下降程度,听力图类型,药物治疗的影响评估HBOT之前提供的数据,发作时间和HBOT疗程数。 HBOT后所有病例的平均听力增益为29.5 dB。在以下情况下,这种获益具有统计学意义:HBOT发作较早(p = 0.016),HBOT会话次数较多(p <0.01),类固醇使用量(p = 0.009),低频上升和总听力图配置(p < 0.01)和严重的听力损失(p = 0.011)。在具有高频率下降听力图配置的情况下,成功率明显较低(p <0.001)。类固醇疗法是影响预后的最重要因素。这项回顾性研究和我们的临床经验表明,在疾病的早期与类固醇一起使用时,HBOT具有有益的作用。由经验丰富的高压团队正确使用HBOT是安全的做法。在ISSNHL的治疗中,除了一些轻微的副作用外,在2.5 ATA时可以耐受20次HBOT。对于完全或严重听力损失的病例,应考虑使用HBOT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号